Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Yescarta (axicabtagene ciloleucel by Year
Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) — Europe sales ($M) ($M)
Gilead Sciences Yescarta (axicabtagene ciloleucel: $598M in FY2025, down 10.2% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 598 | -10.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 666 | +21.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 547 | +54.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 355 | +40.3% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 253 | +32.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 191 | +130.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 83 | +8,200.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 1 | – | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Yescarta (axicabtagene ciloleucel ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-yescarta-eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.